[go: up one dir, main page]

HK1039059A1 - 负调节对治疗蛋白的免疫应答的方法 - Google Patents

负调节对治疗蛋白的免疫应答的方法 Download PDF

Info

Publication number
HK1039059A1
HK1039059A1 HK02100157.7A HK02100157A HK1039059A1 HK 1039059 A1 HK1039059 A1 HK 1039059A1 HK 02100157 A HK02100157 A HK 02100157A HK 1039059 A1 HK1039059 A1 HK 1039059A1
Authority
HK
Hong Kong
Prior art keywords
methods
therapeutic proteins
downmodulating
immune response
agents
Prior art date
Application number
HK02100157.7A
Other languages
English (en)
Chinese (zh)
Inventor
Qian Jiahua
W Hoyer Leon
Collins Mary
S Gray Gary
Original Assignee
Genetics Institute, Llc
American Red Cross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute, Llc, American Red Cross filed Critical Genetics Institute, Llc
Publication of HK1039059A1 publication Critical patent/HK1039059A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK02100157.7A 1998-09-21 1999-09-21 负调节对治疗蛋白的免疫应答的方法 HK1039059A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21
US09/158,178 1998-09-21
PCT/US1999/021991 WO2000016801A1 (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins

Publications (1)

Publication Number Publication Date
HK1039059A1 true HK1039059A1 (zh) 2002-04-12

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02100157.7A HK1039059A1 (zh) 1998-09-21 1999-09-21 负调节对治疗蛋白的免疫应答的方法

Country Status (21)

Country Link
EP (1) EP1115423A1 (lt)
JP (1) JP2002526455A (lt)
KR (1) KR20010085830A (lt)
CN (1) CN1331602A (lt)
AU (1) AU761206B2 (lt)
BR (1) BR9913991A (lt)
CA (1) CA2343916A1 (lt)
CZ (1) CZ20011021A3 (lt)
EA (1) EA005236B1 (lt)
HK (1) HK1039059A1 (lt)
HU (1) HUP0103960A3 (lt)
IL (1) IL142069A0 (lt)
LT (1) LT4920B (lt)
LV (1) LV12768B (lt)
MX (1) MXPA01002898A (lt)
NO (1) NO20011412L (lt)
NZ (1) NZ511034A (lt)
PL (1) PL346796A1 (lt)
SI (1) SI20626A (lt)
WO (1) WO2000016801A1 (lt)
ZA (1) ZA200103156B (lt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
JP2003534291A (ja) * 2000-05-19 2003-11-18 ザ センター フォー ブラッド リサーチ インク Ｐ−セレクチン活性の変調による止血障害の診断及び治療方法
WO2005010483A2 (en) * 2003-06-10 2005-02-03 Smiths Detection Inc. Sensor arrangement
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
CA2110518C (en) 1991-06-27 2007-05-22 Peter S. Linsley Ctla4 receptor, fusion proteins containing it and uses thereof
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
WO1996005860A1 (en) * 1994-08-19 1996-02-29 Novo Nordisk A/S A method of treating a patient with a biologically active compound
CA2200869A1 (en) * 1994-10-19 1996-05-02 Bruce C. Trapnell Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
JP4751493B2 (ja) * 1996-03-20 2011-08-17 ブリストル−マイヤーズ スクイッブ カンパニー Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物
ATE356634T1 (de) * 1997-01-10 2007-04-15 Biogen Idec Inc Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
AU733062B2 (en) * 1997-06-20 2001-05-03 Biogen Idec Ma Inc. CD154 blockade therapy for therapeutic protein inhibitor syndrome
US8112896B2 (en) 2009-11-06 2012-02-14 Hexagon Metrology Ab Articulated arm

Also Published As

Publication number Publication date
AU6057899A (en) 2000-04-10
BR9913991A (pt) 2001-07-03
NO20011412D0 (no) 2001-03-20
CA2343916A1 (en) 2000-03-30
LT4920B (lt) 2002-06-25
HUP0103960A2 (hu) 2002-02-28
PL346796A1 (en) 2002-02-25
AU761206B2 (en) 2003-05-29
WO2000016801A9 (en) 2000-10-26
KR20010085830A (ko) 2001-09-07
CZ20011021A3 (cs) 2001-10-17
JP2002526455A (ja) 2002-08-20
HUP0103960A3 (en) 2003-09-29
EP1115423A1 (en) 2001-07-18
EA005236B1 (ru) 2004-12-30
NO20011412L (no) 2001-05-16
LT2001045A (lt) 2002-01-25
SI20626A (sl) 2002-02-28
IL142069A0 (en) 2002-03-10
LV12768A (en) 2001-12-20
MXPA01002898A (es) 2002-06-04
EA200100385A1 (ru) 2001-10-22
NZ511034A (en) 2004-03-26
WO2000016801A1 (en) 2000-03-30
LV12768B (lv) 2002-06-20
CN1331602A (zh) 2002-01-16
ZA200103156B (en) 2002-07-18

Similar Documents

Publication Publication Date Title
IL159422A0 (en) Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
EP1420009A3 (en) Novel amino acid derivatives with improved multi-drug resistance activity
DE69727142D1 (de) Verwendung eines bpi proteinproduktes als antithrombotisches mittel
WO2002015920A3 (en) Treatment of hyperproliferative diseases
AU2085201A (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
EP2305269A3 (en) Immunemodulating oligosaccharides
WO2002049593A3 (de) Verwendung von dna-reparatur-enzymen als mmp-1-inhibitoren
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
WO1997040072A3 (en) Adam proteins and uses thereof
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
AU2804297A (en) Method of and composition for treating disorders of the skin using vitamin k
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
WO1996040743A3 (en) Inhibitors of factor xa
AU6539000A (en) Composition and method for treating disease by increasing activated alpha2 macroglobulin in the blood and extravascular tissue
BG101126A (en) The use of muramylpeptide compounds
HK1039059A1 (zh) 负调节对治疗蛋白的免疫应答的方法
WO1996013498A3 (en) L-erythrosyl nucleosides
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
AU4823999A (en) Methods and compositions for treating diseases mediated by transglutaminase activity
BR9604882A (pt) Terapia de combinação de inibidor de enzima de conversão de antgiotensina e quantidade de efeito colateral reduzido de antagonista de aldosterona para tratamento de doença cardiovascular
WO1999058098A8 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
CA2136841A1 (en) Novel Piperidyl Amides, Sulfonamides and Sulfoxamides as Inhibitors of Cholesterol Biosynthesis
AU2001283199A1 (en) Methods and compositions for the diagnosis and treatment of brown adipose cell disorders
ATE197645T1 (de) Immunoenzymatisches konjugat, herstellungsverfahren dafür und verwendungen